Table 1.
Patient initials | Age | Indication for NIPT | Date of blood draw | Type of tumor | Type of aneuploidy | Adherence to post-partum follow-up | Full-term pregnancy | Cancer stage | Type of treatment for cancer | Vital status |
---|---|---|---|---|---|---|---|---|---|---|
AR | 34 | PC | May 4, 2021 | None | Multiple | Yes | Yes | NA | None | A, NED |
AV | 29 | PC | November 6, 2019 | FTC | Multiple | Yes | Yes | Stage I | Surgery | A, NED |
BMV | 39 | MAP | June 15, 2021 | Unknowna | Multiple | No | Yes | Unknown | Unknown | LFU |
CMP | 31 | PC | October 14, 2021 | Uterin myoma | Multiple | Yes | Yes | NA | Surgery | A, NED |
CS | 39 | Age | March 3, 2021 | Uterin myoma | Multiple | Yes | Yes | NA | Surgery | A, NED |
Ca Ma | 42 | MAP | January 8, 2022 | Unknowna | Multiple | No | Yes | Unknown | Unknown | LFU |
Cr Ma | 38 | Age | December 19, 2018 | None | Multiple | Yes | Yes | NA | None | A, NED |
CD | 30 | PC | February 4, 2022 | Unknowna | Multiple | No | Yes | Unknown | Unknown | LFU |
EE | 36 | Age | December 28, 2020 | STS | Single (13) | No | Yes | Stage IV | CT | D (May 6, 2022) progression of STS |
Fa Va | 26 | PC | June 14, 2021 | NHL | Multiple | Yes | Yes | Stage II | Rituximab + RT | A, NED |
Fe Va | 28 | PC | December 6, 2018 | NHL | Multiple | Yes | Yes | Stage I | RT | A, NED |
FF | 37 | Age | April 12, 2022 | SFT of SNC | Multiple | Yes | Yes | Diameter 2 cm, no metastases | Surgery | A, NED |
FL | 39 | Age | April 26, 2022 | Unknowna | Multiple | No | Yes | Unknown | Unknown | LFU |
FR | 35 | Age | June 16, 2021 | None | Multiple | Yes | Yes | None | None | A, NED |
LB | 37 | Age | September 25, 2021 | BC | Multiple | Yes | No | Stage I | Surgery + HT | A, NED |
LR | 35 | Age | November 29, 2021 | Breast fibroadenoma | Multiple | Yes | Yes | NA | Surgery | A, NED |
Mar Car | 39 | Age | September 8, 2022 | NHL | Multiple | Yes | Yes | Stage II | Rituximab + RT | A, NED |
Mas Car | 35 | MAP | August 10, 2021 | Unknowna | Multiple | No | Unknown | Unknown | Unknown | LFU |
PA | 40 | Previous T21 | January 25, 2020 | Colon | Multiple | No | Yes | Stage II | Surgery | A, NED |
PF | 34 | PC | December 22, 2021 | NHL | Multiple | Yes | Yes | Stage II | RT | A, NED |
PMR | 33 | MAP | May 18, 2021 | None | Multiple | Yes | Yes | NA | None | A, NED |
PJ | 28 | PC | June 29, 2021 | BC | Multiple | No | Yes | Stage I | Surgery + HT | D (Sept 22, 2022) progression of BC |
PE | 40 | Age | August 25, 2021 | Unknowna | Multiple | No | No | Unknown | Unknown | LFU |
TG | 45 | MAP | January 7, 2022 | Breast fibroadenoma | Multiple | Yes | Yes | NA | Surgery | A, NED |
TP | 35 | Age | January 26, 2021 | Unknowna | Multiple | No | Unknown | Unknown | Unknown | LFU |
VMC | 23 | PC | February 19, 2021 | NHL | Multiple | Yes | Yes | Stage I | RT | A, NED |
WN | 26 | PC | September 6, 2019 | Colon | Multiple | Yes | Yes | Stage II | Surgery | A, NED |
A, alive; BC, breast cancer; CT, chemotherapy; D, dead; FTC, follicular thyroid carcinoma; HT, hormone therapy; LFU, lost to follow-up; MAP, medically-assisted procreation; NED, no evidence of disease; NHL, non-Hodgkin lymphoma; PC, personal choice; RT, radiotherapy; SFT, solitary fibrous tumor; STS, soft tissue sarcoma.
These patients did not want to undergo any further diagnostic investigations or release any additional information. Indirect information obtained through the treating physician suggests a high probability that they may have developed cancer.